HAP CareSource MI Coordinated Health List of Covered Drugs (Drug List)
Customize your policy alerts
Sign up for all CareSource policy alerts
Know when CareSource releases new policies or updates existing guidance.
Monitor payer policy activity
This document is the Plan's List of Covered Drugs (Drug List) for HAP CareSource MI Coordinated Health describing covered drugs, restrictions (prior authorization, quantity limits, step therapy), member rights (exceptions, transitions), pharmacy supply options (mail-order, retail), and FAQs. It applies to plan members using network pharmacies and explains rules for Medicare and Michigan Medicaid covered drugs.
No material clinical or coverage changes — this excerpt is an updated segment of the drug list showing update dates (last updated 03/13/2026 and document updated 04/01/2026).
Document version 9, Formulary ID 00026143; Drug List updated on 04/01/2026; some table portions note last updated 03/13/2026.
Coverage Summary
General coverage / member eligibility
This Drug List covers medications and certain OTC products available to HAP CareSource MI Coordinated Health members. Covered drugs must be medically necessary, prescribed by a licensed provider, and dispensed at a HAP CareSource network pharmacy. The plan follows Medicare and Michigan Medicaid rules; some products may have special pharmacy network, quantity, prior authorization, step therapy, or other utilization controls. Changes to the Drug List (adds/removals or rule changes) follow federal/state requirements and members may request exceptions or transition supplies when rules change.
Drug List change exceptions / transition supplies
Transition supplies, formulary change exceptions, and appeals (exceptions) are available to members under Medicare and Medicaid rules. The following criteria groups describe how members and providers can obtain transition supplies, request a formulary exception, and the utilization controls applied per drug.
Exception (appeal) requests
Members and prescribers may request an exception (also called an appeal) when coverage is denied or a drug is subject to utilization controls. The plan processes exceptions per regulatory timelines and offers expedited reviews when delay would risk health.
ALL of the following
- A request for an exception must state why the formulary drug or coverage rule is not suitable and include supporting clinical information.
- Expedited (urgent) exception requests are available when the prescriber certifies that waiting for a standard decision could seriously harm the member.
- The plan will notify the member and prescriber of the decision within the timeframes required by Medicare and Michigan Medicaid; approval includes any limits (e.g., quantity, duration).
- If an exception is denied, members receive notice with reason and instructions for internal appeal and external review rights.
Utilization Controls by Drug (per-line entries)
Utilization controls are applied at the drug or formulation level and may include prior authorization, quantity limits, step therapy, age or diagnosis restrictions, refill timing, or specialty pharmacy requirements. The plan enforces these per-line (per product/NDC/formulation) rules as listed on the Drug List.
Per-drug utilization management requirements (listed per product)
Per-drug utilization management requirements (examples summarized; see the Drug List for each product's specific rules). Each listed product entry includes formulary tier, coverage status, and any of the above utilization controls.
Formulary entry controls
Formulary entry controls govern how drugs are placed on the Drug List and what utilization restrictions apply when they are listed. Controls include tiering, PA, step edits, quantity limits, and specialty designation.
Formulary entries and utilization controls
Formulary listings include specific utilization controls for each drug/formulation. The Drug List indicates coverage actions (covered, not covered, PA required, quantity limit, step therapy) and any restrictions by formulation or route.
Formulary listing usage rules (implicit)
Usage rules and coverage restrictions are applied as implicit policy logic across the Drug List: prescribers must follow documented PA and step therapy processes; pharmacies must adjudicate claims per listed quantity and refill rules.
Coverage actions/limits included in list
The Drug List includes numerous coverage actions and limits. Examples of coverage actions applied to listed drugs include denial for lack of PA, approval with a specified quantity limit, or coverage contingent on step therapy completion.
Coverage / Restrictions entries (per listed drug/formulation)
Individual Drug/Formulation coverage and restrictions are listed on the Drug List pages. Each entry includes product name, formulation, coverage status, and any utilization controls or restrictions applicable to that product.
Transition Supplies, Exceptions & Provider Responsibilities
Utilization Controls (PA, QL, ST, NDS, LA, MCD)
Applicable Codes & NDC Constraints
| MO | Medication-only / medical benefit flag used in formulary listings |
| PA | Prior Authorization required flag |
| MO (amphotericin b) | Amphotericin B formulations flagged as medication-only |
| MO (amphotericin b liposome) | Amphotericin B liposomal formulation flagged as medication-only |
| MO (fluconazole) | Fluconazole flagged as medication-only |
| PA | Prior authorization required |
| QL | Quantity limit applies |
| ST | Step therapy required |
| MO | Medication-only (medical administration) |
| MO examples | Example drugs commonly carrying UM flags: BIKTARVY (PA/QL), CABENUVA (PA), BARACLUDE (PA/QL), TROGARZO (PA), ODEFSEY (PA), STRIBILD (PA/QL) |
| 61314* | NDC prefix used for select specialty/packaged products (e.g., PYZCHIVA mapping) |
| 00054* | NDC prefix grouping—multiple injectable/oral generics |
| 00093* | NDC prefix grouping—various products |
| 00781* | NDC prefix grouping—injectable/packaged products |
| 17270* | NDC prefix grouping—branded specialty products |
| 45802* | NDC prefix grouping—oral solids/liquids |
| 60687* | NDC prefix grouping—antivirals/antibiotics |
| 68180* | NDC prefix grouping—injectables/oncology agents |
| 69097* | NDC prefix grouping—specialty biologics and injectables |
| amphotericin b | flagged MO; may require PA for inpatient/outpatient administration |
| amphotericin b liposome | flagged MO; high-cost liposomal formulation—PA commonly required |
| fluconazole | often subject to QL for recurring courses |
| CRESEMBA ORAL (isavuconazole) | antifungal—PA and QL may apply |
| itraconazole oral capsule | antifungal—PA/QL possible |
| ketoconazole oral | systemic ketoconazole—safety restrictions; PA likely |
| BIKTARVY | antiretroviral—PA/QL flags common |
| CABENUVA | long-acting injectable antiretroviral—PA required |
| BARACLUDE | antiviral (entecavir)—PA/QL possible |
| darunavir (various formulations) | antiretroviral—PA/QL depending on formulation |
Quick Actions for Clinical/Billing Staff
Revision History
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.